ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2013 Financial Results and Provides Quarterly Update
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) antibody-drug conjugate (ADC) technology, today reported financial results for the three-month period ended March 31, 2013 – the third quarter of the Company’s 2013 fiscal year – and provided an update on the Company.
Help employers find you! Check out all the jobs and post your resume.
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) antibody-drug conjugate (ADC) technology, today reported financial results for the three-month period ended March 31, 2013 – the third quarter of the Company’s 2013 fiscal year – and provided an update on the Company.
Help employers find you! Check out all the jobs and post your resume.